



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	3.10
Trade Time:	4:00 PM ET May 25, 2017
Change:	0.00 (0.000%)
Day Range	3.05 - 3.13
52-Week Range	2.85 - 5.13
Volume	1,579,016
Market Cap. (\$M)	387.841
Shares Out (M)	125.110

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*May 17, 2017*

[Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting](#)

*May 9, 2017*

[Celldex Reports First Quarter 2017 Results](#)

*Mar 14, 2017*

[Celldex Provides Corporate Update and Reports Full Year 2016 Results](#)

*Mar 1, 2017*

[Celldex Therapeutics Announces Appointment to Board of Directors](#)

*Feb 13, 2017*

[Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

*Mar 14, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Definitive Proxy Statement](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 7, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2016*

[Quarterly Report \(10-Q\)](#)